AIM vs. NKGN, EVAX, APTO, PLUR, SRZN, PMCB, INAB, INKT, ACHL, and TARA
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include NKGen Biotech (NKGN), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Pluri (PLUR), Surrozen (SRZN), PharmaCyte Biotech (PMCB), IN8bio (INAB), MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), and Protara Therapeutics (TARA). These companies are all part of the "biological products, except diagnostic" industry.
AIM ImmunoTech (NYSE:AIM) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
AIM ImmunoTech has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
AIM ImmunoTech has higher revenue and earnings than NKGen Biotech.
In the previous week, NKGen Biotech had 4 more articles in the media than AIM ImmunoTech. MarketBeat recorded 5 mentions for NKGen Biotech and 1 mentions for AIM ImmunoTech. NKGen Biotech's average media sentiment score of 0.17 beat AIM ImmunoTech's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the news media.
AIM ImmunoTech received 56 more outperform votes than NKGen Biotech when rated by MarketBeat users.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 20.0% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
NKGen Biotech has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -14,337.62%. NKGen Biotech's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
Summary
NKGen Biotech beats AIM ImmunoTech on 9 of the 12 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
